{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:23:12Z","timestamp":1790875392291,"version":"4.1.0"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.mrfmmm.2019.111674","type":"journal-article","created":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T10:29:25Z","timestamp":1562408965000},"page":"111674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Molecular pathogenesis of gallbladder cancer: An update"],"prefix":"10.1016","volume":"816-818","author":[{"given":"Shravan Kumar","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niraj","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra","family":"Krishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mrfmmm.2019.111674_bib0005","series-title":"Gallbladder Cancer : Can Newer Insights Improve the Outcome?","first-page":"642","author":"Dutta","year":"2012"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0010","article-title":"Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas","author":"Dhir","year":"1999","journal-title":"Indian J. Gastroenterol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0015","doi-asserted-by":"crossref","DOI":"10.5009\/gnl.2012.6.2.172","article-title":"Epidemiology of gallbladder disease: cholelithiasis and cancer","author":"Stinton","year":"2012","journal-title":"Gut Liver"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0020","series-title":"Gallbladder Cancers : Associated Conditions, Histological Types, Prognosis, and Prevention","first-page":"562","author":"Cariati","year":"2012"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0025","first-page":"1","article-title":"Analysis of prognostic factors for survival after surgery for gallbladder cancer based on a Bayesian network","author":"Cai","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0030","series-title":"Gallbladder Cancer: A Global Perspective","first-page":"607","author":"Kapoor","year":"2006"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0035","series-title":"Gallbladder Adenomas Have Molecular Abnormalities Different From Those Present in Gallbladder Carcinomas","first-page":"21","author":"Wistuba","year":"2019"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0040","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1872-034X.2008.00356.x","article-title":"Stones from cancerous and benign gallbladders are different: a proton nuclear magnetic resonance spectroscopy study","volume":"38","author":"Srivastava","year":"2008","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0045","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/ng.3386","article-title":"Building a staircase to precision medicine for biliary tract cancer","volume":"47","author":"Razumilava","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0050","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(17)30167-5","article-title":"Common genetic variation and risk of gallbladder cancer in India: acase-control genome-wide association study","volume":"18","author":"Mhatre","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0055","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/gut.52.5.706","article-title":"Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma","volume":"52","author":"Tannapfel","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0060","first-page":"3156","article-title":"K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China","volume":"8","author":"Rashid","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0065","series-title":"Multiple K-ras Codon 12 Mutations in Cholangiocarcinomas Demonstrated With a Sensitive Polymerase Chain Reaction Technique1","author":"Levi","year":"1991"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0070","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1111\/j.1572-0241.1999.01155.x","article-title":"Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct","volume":"94","author":"Hanada","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0075","series-title":"Mutations in Intrahepatic Cholangiocarcinoma of the Liver","first-page":"721","author":"Tannapfel","year":"2000"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0080","series-title":"Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 Mutations and Microsatellite Instability","first-page":"179","author":"Saetta","year":"2004"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0085","series-title":"The V599E BRAF Mutation Is Uncommon in Biliary Tract Cancers","first-page":"1386","author":"Goldenberg","year":"2004"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0090","series-title":"Human Cancer Biology Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma","first-page":"1680","author":"Leone","year":"2006"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0095","series-title":"Original paper Detection of Response-predicting Mutations in the Kinase Domain of the Epidermal Growth Factor Receptor Gene in Cholangiocarcinomas","first-page":"649","author":"Chung","year":"2005"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0100","series-title":"Rare PIK3CA Hotspot Mutations in Carcinomas of the Biliary Tract","first-page":"363","author":"Riener","year":"2008"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0105","series-title":"Smad4 \u035e DPC4-mediated Tumor Suppression Through Suppression of Angiogenesis","author":"Bouck","year":"2000"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0110","series-title":"Alterations of p16 and Prognosis in Biliary Tract Cancers From a Population- Based Study in China","first-page":"1717","author":"Ueki","year":"2004"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0115","series-title":"Mutations of p53 Tumor Suppressor Gene, Apoptosis, and Proliferation in Intrahepatic Cholangiocellular Carcinoma of the Liver","first-page":"317","author":"Tannapfel","year":"2000"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/(SICI)1096-9098(200003)73:3<158::AID-JSO9>3.0.CO;2-N","article-title":"Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer","volume":"73","author":"Suto","year":"2000","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0304-3835(01)00562-6","article-title":"Genetic alterations in gallbladder adenoma, dysplasia and carcinoma","volume":"169","author":"Kim","year":"2001","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0130","series-title":"Genetics of Biliary Tract Cancers and Emerging Targeted Therapies","first-page":"3531","author":"Hezel","year":"2010"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0135","series-title":"Amplification and Overexpression of C- Erb B-2, Epidermal Growth Factor Receptor, and C- Met in Biliary Tract Cancers","first-page":"356","author":"Nakazawa","year":"2005"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0140","series-title":"Chemotherapy in Advanced Biliary Tract Carcinoma : a Pooled Analysis of Clinical Trials","first-page":"896","author":"Eckel","year":"2007"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-2407-11-60","article-title":"Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma","volume":"11","author":"Deshpande","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0150","series-title":"Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis","first-page":"10","author":"Chang","year":"2015"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0155","series-title":"O.F. Clinical, 2013 EDUCATIONAL BOOK American Society of Clinical Oncology Educational Book","author":"Society","year":"2013"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0160","first-page":"2129","author":"Okimoto","year":"2004","journal-title":"N. Engl. J."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0165","first-page":"683","article-title":"Alpha-glycerolphosphate dehydrogenase activity in rabbit organs and tissues in various endocrine disorders","volume":"25","author":"Ablaev","year":"1979","journal-title":"Vopr. Med. Khim."},{"issue":"80-","key":"10.1016\/j.mrfmmm.2019.111674_bib0170","article-title":"Mutations in lung Cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0175","first-page":"219","article-title":"Cell lipids and sensitivity of bacteria to antibiotics","volume":"16","author":"Mordarska","year":"1968","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0180","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/gtmb.2012.0510","article-title":"Companion diagnostic testing for targeted cancer therapies: an overview","volume":"17","author":"Fan","year":"2013","journal-title":"Genet. Test. Mol. Biomark."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035309","article-title":"Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials","volume":"7","author":"Lovly","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0190","series-title":"Advances in Brief Allele-specific Mutations Involved in the Pathogenesis of Endemic Gallbladder Carcinoma in Chile1","first-page":"2511","author":"Wistuba","year":"1995"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0046-8177(99)90295-2","article-title":"Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas","volume":"30","author":"Wistuba","year":"1999","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/0377-4929.130849","article-title":"Mutation profiling in gallbladder cancer in Indian population","volume":"57","author":"Kumari","year":"2014","journal-title":"Indian J. Pathol. Microbiol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0205","article-title":"&Em&PIK3CA&\/em& mutations in gallbladder cancers","volume":"66","author":"Shigematsu","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0210","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jfma.2016.07.015","article-title":"Mutation analysis and copy number changes of KRAS and BRAF genes in Taiwanese cases of biliary tract cholangiocarcinoma","volume":"116","author":"Huang","year":"2017","journal-title":"J. Formos. Med. Assoc"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0215","series-title":"Gallbladder Cancer : A Cancer Awaiting Targeted Therapy","first-page":"1","author":"Roa","year":"2016"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0220","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ng.3030","article-title":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","volume":"46","author":"Li","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0225","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/PAI.0b013e3181f09179","article-title":"Mutations in the RAS\/RAF\/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas","volume":"19","author":"Pai","year":"2011","journal-title":"Appl. Immunohistochem. Mol. Morphol"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0230","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/jco.2015.33.3_suppl.286","article-title":"Next-generationsequencing:profilinggallbladdercancer(GBC)","volume":"33","author":"Chiu","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0235","series-title":"Adenocarcinomas of the Gallbladder From United States Patients Demonstrate Less Frequent Molecular Change for Several Genetic Markers Than Other Intra-abdominal","first-page":"337","author":"Zauber","year":"2013"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0240","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4137\/JCM.S40549","article-title":"KRAS mutation as a potential prognostic biomarker of biliary tract cancers","volume":"7","author":"Yokoyama","year":"2016","journal-title":"Japanese Clin. Med."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0245","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next- generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0250","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/jco.2015.33.15_suppl.4009","article-title":"Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations","volume":"33","author":"Ross","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0255","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/jgh.12505","article-title":"Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan","volume":"29","author":"Chang","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0260","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3892\/ol.2017.6224","article-title":"Genetic alterations in Japanese extrahepatic biliary tract cancer","volume":"14","author":"Noguchi","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0265","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/j.gastro.2008.06.082","article-title":"Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder Cancer","volume":"135","author":"Shibata","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0270","doi-asserted-by":"crossref","unstructured":"A. Sharma, A. Kumar, N. Kumari, N. Krishnani, N. Rastogi, A. Kumar, N. Kumari, N. Krishnani, N. Rastogi, (2017).doi:10.1016\/j.mgene.2017.07.009.","DOI":"10.1016\/j.mgene.2017.07.009"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0275","first-page":"955","article-title":"K-ras gene mutation in gallbladder carcinoma","volume":"132","author":"T.O. Roa","year":"2004","journal-title":"Rev. Med. Chil."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0280","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1440-1746.2004.03355.x","article-title":"Mutational spectrum of K-ras oncogene among Indian patients with gallbladder cancer","volume":"19","author":"Singh","year":"2004","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0285","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000353133","article-title":"Prognostic significance of K-ras codon 12 mutation in patients with resected gallbladder Cancer","volume":"30","author":"Kazmi","year":"2013","journal-title":"Dig. Surg."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0290","series-title":"Relation Between K- Ras Codon 12 Mutation and p53 Protein Overexpression in Gallbladder Cancer and Biliary Ductal Epithelia in Patients With Pancreaticobiliary Maljunction","first-page":"198","author":"Masuhara","year":"2000"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0295","series-title":"Identification of MAP Kinase Pathways As Therapeutic Targets in Gallbladder Carcinoma Using Targeted Parallel Sequencing","first-page":"36319","author":"Li","year":"2017"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0300","first-page":"1","article-title":"Genetic analysis of brazilian patients with gallbladder Cancer","author":"S\u00e1bato","year":"2018","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0305","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1089\/gtmb.2010.0194","article-title":"A novel polymorphism in codon 25 of the KRAS gene associated with gallbladder carcinoma patients of the eastern part of India","volume":"15","author":"Pramanik","year":"2011","journal-title":"Genet. Test. Mol. Biomarkers"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0310","first-page":"289","article-title":"Tumor protein p53 and K -ras gene mutations in peruvian patients with gallbladder","volume":"20","author":"Vidaurre","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0315","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jmoldx.2015.12.003","article-title":"Somatic mutations of PI3K in early and advanced gallbladder Cancer: additional options for an orphan Cancer","volume":"18","author":"Roa","year":"2016","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0320","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/jco.2015.33.3_suppl.231","article-title":"Comprehensive genomic profiling of biliary tract cancers to revealtumor-specific differences and genomic alterations","volume":"33","author":"Ross","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0325","series-title":"BRAF V600E-specific Immunohistochemistry Reveals Low Mutation Rates in Biliary Tract Cancer and Restriction to Intrahepatic Cholangiocarcinoma","first-page":"1028","author":"Goeppert","year":"2013"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0330","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0335","first-page":"495","article-title":"Targeted gene sequencing of gallbladder carcinoma identifies high-impact somatic and rare germline mutations","volume":"14","author":"Yadav","year":"2017","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0340","first-page":"1","article-title":"ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder Cancer","author":"Iyer","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0345","series-title":"North Indian Gallbladder Cancer Patients","first-page":"1","author":"Sharma","year":"2019"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0350","first-page":"251","article-title":"[P53 gene mutation in gallbladder cancer]","volume":"128","author":"Roa","year":"2000","journal-title":"Rev. Med. Chil."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0355","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.7314\/APJCP.2014.15.13.5449","article-title":"High frequency of TP53 but not K-ras gene mutations in Bolivian patients with gallbladder cancer","volume":"15","author":"Asai","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0360","series-title":"Genetic Changes of p53, K- Ras, and Microsatellite Instability in Gallbladder Carcinoma in High-incidence Areas of Japan and","first-page":"70","author":"Nagahashi","year":"2008"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0365","series-title":"Original Article","first-page":"96","author":"Nigam","year":"2010"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0370","doi-asserted-by":"crossref","first-page":"705","DOI":"10.18632\/oncotarget.974","article-title":"P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy","volume":"4","author":"Said","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0375","doi-asserted-by":"crossref","first-page":"1680LP","DOI":"10.1158\/1078-0432.CCR-05-1692","article-title":"Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma","volume":"12","author":"Leone","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0380","article-title":"Genomic &em&ERBB2&\/em&\/&em&ERBB3&\/em& mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis","author":"Li","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0385","first-page":"19LP","article-title":"More frequent \u03b2-Catenin exon 3 mutations in gallbladder adenomas than in carcinomas indicate different lineages","volume":"61","author":"Yanagisawa","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0390","series-title":"HHSPublicAccess","first-page":"701","author":"Profiling","year":"2015"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0395","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in Cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0400","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrc1279","article-title":"The history of cancer epigenetics","volume":"4","author":"Feinberg","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0405","first-page":"125","article-title":"Transcriptional gene silencing by short interfering RNAs","volume":"7","author":"Kawasaki","year":"2005","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0410","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4161\/epi.3.1.5555","article-title":"Epigenetic mechanisms of gene regulation during mammalian spermatogenesis","volume":"3","author":"Khalil","year":"2008","journal-title":"Epigenetics"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0415","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/5947","article-title":"Cancer-epigenetics comes of age","volume":"21","author":"Jones","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0420","series-title":"Cancer As an Epigenetic Disease : DNA Methylation and Chromatin Alterations in Human Tumours","first-page":"1","author":"Esteller","year":"2002"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0425","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mc.20457","article-title":"Promoter methylation profile in preneoplasticand neoplastic gallbladder lesions","volume":"48","author":"Garc\u00eda","year":"2008","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0430","series-title":"Frequent Epigenetic Inactivation of Chromosome 3p Candidate Tumor Suppressor Genes in Gallbladder Carcinoma","first-page":"100","author":"Riquelme","year":"2007"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0435","article-title":"Promoter methylation of &strong&&em&INK4a\/ARF&\/em&&\/strong& As detected in Bile-Significance for the differential diagnosis in biliary disease","volume":"9","author":"Klump","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0440","series-title":"Two Distinct Pathways of p16 Gene Inactivation in Gallbladder Cancer","first-page":"6396","author":"Tadokoro","year":"2007"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0445","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000100478","article-title":"Frequent occurrence of abnormal E-Cadherin\/\u03b2-Catenin protein expression in advanced gallbladder cancers and its association with decreased apoptosis","volume":"71","author":"Hirata","year":"2006","journal-title":"Oncology"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0450","series-title":"Cancer Epigenetics: Above and Beyond","first-page":"275","author":"Brait","year":"2012"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0455","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2217\/fon.14.165","article-title":"Global and gene-specific DNA methylation pattern discriminates cholecystitis from gallbladder cancer patients in Chile","volume":"11","author":"Kagohara","year":"2015","journal-title":"Future Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0460","series-title":"Gene Methylation Patterns in Digestive Tumors","author":"Roa","year":"2008"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0465","series-title":"Promoter Methylation Profile in Gallbladder Cancer","first-page":"269","author":"J.C. R","year":"2006"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0470","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-04-0579","article-title":"Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis","volume":"10","author":"Takahashi","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0475","series-title":"Progression of Gene Hypermethylation in Gallstone Disease Leading to Gallbladder Cancer","author":"House","year":"2003"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0480","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1349-7006.2004.tb03254.x","article-title":"Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients","volume":"95","author":"Tozawa","year":"2005","journal-title":"Cancer Sci."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0485","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1245\/ASO.2005.07.020","article-title":"Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers","volume":"12","author":"Koga","year":"2005","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0490","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cancergen.2015.09.007","article-title":"Effects of PTEN gene alteration in patients with gallbladder cancer","volume":"208","author":"Ali","year":"2018","journal-title":"Cancer Genet."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0495","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.4103\/0971-5916.191792","article-title":"Tiwari, Epigenetic regulation of APC in the molecular pathogenesis of gallbladder cancer","volume":"143","author":"Tekcham","year":"2016","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0500","series-title":"Prognostic Significance of Promoter DNA Hypermethylation of the Cysteine Dioxygenase 1 (CDO1) Gene in Primary Gallbladder Cancer and Gallbladder Disease","first-page":"1","author":"Igarashi","year":"2017"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2017.04.034","article-title":"WNT inhibitory factor 1 promoter hypermethylation is an early event during gallbladder cancer tumorigenesis that predicts poor survival","author":"Lin","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0510","first-page":"1369","article-title":"[Inactivation of CDKN2A gene (p16) in gallbladder carcinoma]","volume":"132","author":"Roa","year":"2004","journal-title":"Rev. Med. Chil."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0515","series-title":"The Genetic Basis of Human Cancer","author":"K.K. Vogelstein","year":"2002"},{"issue":"80-","key":"10.1016\/j.mrfmmm.2019.111674_bib0520","first-page":"1959","article-title":"Mismatch repair, genetic stability, and cancer","volume":"266","author":"M. P","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0525","series-title":"Mutations of a mutS Homolog in Hereditary Nonpolyposis Colorectal Cancer","first-page":"1215","author":"Leach","year":"1993"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0530","series-title":"Clues to the Pathogenesis of Familial Colorectal Cancer","first-page":"260","author":"Aaltonen","year":"1993"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0535","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/(SICI)1097-0215(19970904)72:5<762::AID-IJC10>3.0.CO;2-B","article-title":"High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma","volume":"72","author":"D.G. Dahiya","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0540","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1471-4914(01)01916-5","article-title":"Microsatellite instability as a tool forthe classification of gastric cancer","volume":"7","author":"P.S. Simpson","year":"2001","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0545","series-title":"Microsatellite Instability and hMLH1\/hMSH2 Expression in Young Endometrial Carcinoma Patients: Associations With Family History and Histopathology","author":"Parc","year":"2000"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0550","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/1097-0215(20000920)89:5<444::AID-IJC8>3.0.CO;2-F","article-title":"Microsatellite instability, prognosis and metastasis in gastric cancers from a low-risk population","volume":"89","author":"Schneider","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0555","series-title":"Microsatellite Instability in Gallbladder Carcinoma","first-page":"393","author":"Moy","year":"2015"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0560","first-page":"573","article-title":"frequency of genetic alterations observed in cell cycle regulatory proteins and microsatellite instability in gallbladder adenocarcinoma: a translational perspective","volume":"12","author":"Mishra","year":"2011","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0565","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00428-010-0908-6","article-title":"Role of E-cadherin gene in gall bladder cancer and its precursor lesions","volume":"456","author":"A.S. Priya","year":"2010","journal-title":"Virchows Arch."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0570","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/07357900802711304","article-title":"Fragile histidine triad (FHIT) gene and its association with p53 protein expression in the progression of gall bladder Cancer","volume":"27","author":"Priya","year":"2009","journal-title":"Cancer Invest."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0575","series-title":"Microsatellite Instability in Preneoplastic and Neoplastic Lesions of","first-page":"79","author":"Roa","year":"2005"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0580","series-title":"Microsatellite Instability in Chronic Cholecystitis Is Indicative of an Early Stage in Gallbladder Carcinogenesis","author":"Yanagisawa","year":"2003"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0585","series-title":"Genome-wide Allelotyping Analysis Reveals Multiple Sites of Allelic Loss in Gallbladder Carcinoma 1","first-page":"3795","author":"Wistuba","year":"2001"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0590","series-title":"Analysis in the Pathogenesis of Gallbladder Carcinoma","first-page":"432","author":"Wistuba","year":"2002"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0595","series-title":"Uveal Melanoma AND","first-page":"2472","author":"Scholes","year":"2018"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0600","series-title":"Loss of Heterozygosity on Chromosomes 3p, 8p, 9p and 17p in the Progression of Squamous Cell Carcinoma of the Larynx","author":"Yoo","year":"2004"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0605","series-title":"Fragile Histidine Triad Gene Abnormalities in the Pathogenesis of Gallbladder Carcinoma","first-page":"2073","author":"Wistuba","year":"2002"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0610","series-title":"Allelotype Analysis of Gallbladder Carcinoma Associated With Anomalous Junction of Pancreaticobiliary Duct","first-page":"135","author":"Nakayama","year":"2001"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0615","series-title":"Sequential Occurrence of Preneoplastic Lesions and Accumulation of Loss of Heterozygosity in Patients With","first-page":"1073","author":"Jain","year":"2014"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0620","series-title":"NIH Public Access","first-page":"987","author":"Diskin","year":"2009"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0625","series-title":"Abnormal Chromosome 8 Copy Number in Stage I to Stage IV Breast Cancer Studied by Fluorescence In Situ Hybridization","first-page":"4608","author":"Mark","year":"2019"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0630","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/onc.2015.209","article-title":"Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy","volume":"35","author":"Liang","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0635","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/dji112","article-title":"Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non\u2013Small-Cell lung Cancer","volume":"97","author":"Cappuzzo","year":"2005","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0640","series-title":"Highly Frequent PIK3CA Amplification Is Associated With Poor Prognosis in Gastric Cancer","author":"Shi","year":"2012"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0645","series-title":"TNK2 Gene Amplification Is a Novel Predictor of a Poor Prognosis in Patients With Gastric Cancer cell Line and Primary Carcinomas","first-page":"189","author":"Shinmura","year":"2014"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0650","series-title":"R E S E a R C H a RT I C L E S APC Gene Deletions in Gastric Adenocarcinomas in a Chinese Population : a Correlation With Tumour Progression","first-page":"60","author":"Fang","year":"2012"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0655","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1038\/onc.2010.143","article-title":"Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma","volume":"29","author":"Guo","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0660","series-title":"Impact of MET Amplification on Gastric Cancer : Possible Roles As a Novel Prognostic Marker and a Potential Therapeutic Target","first-page":"1517","author":"Lee","year":"2011"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0665","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10120-014-0449-9","article-title":"Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer : evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method","author":"Higaki","year":"2016","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0670","series-title":"MYC In Gastric Carcinoma and Intestinal Metaplasia of Young Adults","first-page":"63","author":"Biotech","year":"2010"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0675","series-title":"HER2 Status in Gastric Cancers : a Retrospective Analysis Fromfour Chinese Representative Clinical Centers and Assessment of Its Prognostic Significance","first-page":"3","author":"Sheng","year":"2013"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0680","series-title":"hTERT, MYC And TP53 Deregulation in Gastric Preneoplastic Lesions","author":"Cristina","year":"2012"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0685","series-title":"Copy-number Increase of AURKA in Gastric Cancers in a Chinese Population : a Correlation With Tumor Progression","first-page":"1017","author":"Fang","year":"2011"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0690","series-title":"Identification of Genes With a Correlation Between Copy Number and Expression in Gastric Cancer","author":"Cheng","year":"2012"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0695","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3748\/wjg.v22.i5.1787","article-title":"MicroRNA aberrations: an emerging field for gallbladder cancer management","volume":"22","author":"Chandra","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0700","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3945\/an.111.001206","article-title":"MicroRNA, nutrition, and cancer prevention","volume":"2","author":"Ross","year":"2011","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0705","series-title":"Micrornas in Development and Disease","first-page":"827","author":"Sayed","year":"2011"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0710","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1367-5931(03)00075-9","article-title":"MicroRNAs: key participants in gene regulatory networks","volume":"7","author":"Ke","year":"2003","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0715","series-title":"Profiling of Regulatory microRNA Transcriptomes in Various Biological Processes : a Review","first-page":"501","author":"Shah","year":"2010"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0720","first-page":"131","article-title":"The role of microRNAs in cancer","volume":"79","author":"Stahlhut Espinosa","year":"2006","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0725","series-title":"microRNAs As Oncogenes and Tumor Suppressors","first-page":"1","author":"Zhang","year":"2007"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0730","first-page":"1","article-title":"ScienceDirect MicroRNAs in cancer biology and therapy : current status and perspectives","author":"Price","year":"2014","journal-title":"Genes Dis."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0735","series-title":"Clinical Significance of MicroRNA Expression Profiles and Polymorphisms in Lung Cancer Development and Management, 2011","author":"Megiorni","year":"2011"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0740","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.suronc.2014.04.003","article-title":"A microRNA gene signature for identification of lung cancer","volume":"23","author":"Xue","year":"2014","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0745","doi-asserted-by":"crossref","first-page":"13914","DOI":"10.18632\/oncotarget.4227","article-title":"MicroRNA expression and its implications for diagnosis and therapy of gallbladder cancer","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0750","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3892\/or.2013.2443","article-title":"High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma","volume":"30","author":"Kono","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0755","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jhep.2013.04.034","article-title":"miR-20a triggers metastasis of gallbladdercarcinoma","volume":"59","author":"Chang","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0760","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1039\/c3mb70479c","article-title":"TGF-\u03b2 upregulates miR-182 expression to promote gallbladder cancer metastasis by targeting CADM1","volume":"10","author":"Qiu","year":"2014","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0765","first-page":"1625","article-title":"Increased expression of microRNA-335 predicts a favorable prognosis in primary gallbladder carcinoma","volume":"6","author":"Peng","year":"2013","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0770","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s13277-013-1207-z","article-title":"miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomerelengthintumorstemcells","volume":"35","author":"Jin","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0775","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/cas.12463","article-title":"MicroRNA-135a acts as a putative tumor suppressor by directly targeting very low density lipoprotein receptor in human gallbladder cancer","volume":"105","author":"Zhou","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0780","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3892\/mmr.2015.3461","article-title":"MicroRNA-146b-5p inhibits the growth of gallbladder carcinoma by targeting epidermal growth factor receptor","volume":"12","author":"Cai","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0785","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/cdd.2016.146","article-title":"MicroRNA-29c-5p suppresses gallbladder carcinoma progression by directly targeting CPEB4 and inhibiting the MAPK pathway","volume":"24","author":"Shu","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0790","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317692249","article-title":"MicroRNA-125b predicts clinical outcome and suppressed tumor proliferation and migration in human gallbladder cancer","volume":"39","author":"Yang","year":"2017","journal-title":"Tumor Biol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0795","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.541","article-title":"Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p","volume":"6","author":"Ma","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0800","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1476-4598-13-156","article-title":"Long non-coding RNA HOTAIR, a c-Myc activated driver ofmalignancy, negatively regulates miRNA-130a in gallbladder cancer","volume":"13","author":"Ma","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0805","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.3892\/ijo.2014.2360","article-title":"MicroRNA-26a acts as a tumor suppressor inhibiting gallbladder cancer cell proliferation by directly targeting HMGA2","volume":"45","author":"Zhou","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0810","first-page":"1849","article-title":"miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer","volume":"7","author":"Letelier","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0815","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1007\/s13277-015-3412-4","article-title":"MicroRNA signatures in total peripheral blood of gallbladder cancer patients","volume":"36","author":"Li","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0820","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-08-1608","article-title":"Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma","volume":"15","author":"Gao","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0825","first-page":"1","article-title":"B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal Cancer cells","volume":"8","author":"Shi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0830","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/his.13669","article-title":"Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy","volume":"73","author":"Neyaz","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0835","series-title":"Hepatobiliary Cancers","author":"F.O.R. Patients","year":"2018"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0840","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract Cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0845","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-016-0432-2","article-title":"Genomic profiling of biliary tract cancers and implications for clinical practice","volume":"17","author":"Jain","year":"2016","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0850","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-05-1554","article-title":"The epidermal growth factor receptor pathway a model for targeted therapy the epidermal growth factor receptor pathway a model","volume":"12","author":"Scaltriti","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0855","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1186\/1471-2407-10-631","article-title":"Targeting EGFR\/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas","volume":"10","author":"Pignochino","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0860","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S1470-2045(10)70247-3","article-title":"Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study","volume":"11","author":"Gruenberger","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0865","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1016\/j.ejca.2013.07.143","article-title":"Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study","volume":"49","author":"Rubovszky","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0870","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/bjc.2014.343","article-title":"Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer","volume":"111","author":"Hezel","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0875","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1093\/annonc\/mdt416","article-title":"A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma","volume":"24","author":"Sohal","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0880","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(09)70333-X","article-title":"Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study","volume":"11","author":"Zhu","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0885","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.2010.28.4075","article-title":"Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary Cancer: a phase II consortium study","volume":"28","author":"Lubner","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0890","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-009-0927-7","article-title":"A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer","volume":"64","author":"Ramanathan","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0895","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/annonc\/mdu175","article-title":"Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study","volume":"25","author":"Buzzoni","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0900","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1200\/JCO.2010.33.9473","article-title":"Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers","volume":"29","author":"Bekaii-Saab","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0905","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.mrfmmm.2019.111674_bib0910","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"}],"container-title":["Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027510719300235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027510719300235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T05:43:44Z","timestamp":1764654224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0027510719300235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":182,"alternative-id":["S0027510719300235"],"URL":"https:\/\/doi.org\/10.1016\/j.mrfmmm.2019.111674","relation":{},"ISSN":["1386-1964"],"issn-type":[{"value":"1386-1964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular pathogenesis of gallbladder cancer: An update","name":"articletitle","label":"Article Title"},{"value":"Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mrfmmm.2019.111674","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111674"}}